The Cambridge Probiotic / Antibiotic Trial 2

Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy

SUMMARY

This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.​
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.​
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group

Aim

This randomised, double blind, placebo controlled study investigated the effect of Lab4 probiotic supplementation on antibiotic resistance in the re-growth gut microbiota population following antibiotic therapy.

Method

Results

1. The number of Candida albicans in the Group 1 at the end of antibiotic therapy was significantly higher compared to the Group 2 (*P<0.05).
2. The numbers of facultative anaerobes and enterobacteria were significantly lower in the Group 2 compared to the Group 1 four weeks post antibiotic treatment (*P=0.031 and *P=0.014, respectively)
3. Numbers of patients harbouring antibiotic resistant enterococci increased significantly post antibiotic therapy in the Group 1 (P= 0.012).
4. There was no change in the incidence rate of antibiotic resistance among the patients in the Group 2 post antibiotic therapy.

Conclusion

The supplementation of Lab4 probiotics alongside antibiotic therapy has been shown to reduce the extent of gut microbiota disruption AND to reduce the level of antibiotic resistance within the ‘re-growth’ microbiota.
Scroll to Top